These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1982701)

  • 41. New clinical trials of angiotensin blockade in cardiovascular disease: foreword.
    Julius S
    Am J Hypertens; 2000 May; 13(5 Pt 2):55S-56S. PubMed ID: 10830789
    [No Abstract]   [Full Text] [Related]  

  • 42. [New momentum in cardiovascular therapy. Further development of ACE inhibitors: from captopril to lisinopril].
    Fortschr Med Suppl; 1988; 48():1-11. PubMed ID: 2904396
    [No Abstract]   [Full Text] [Related]  

  • 43. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 44. How do recent developments affect the angiotensin receptor blockers as a class?
    Cardiovasc J Afr; 2009; 20(2):145. PubMed ID: 19421654
    [No Abstract]   [Full Text] [Related]  

  • 45. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 46. [New breakthrough for ACE inhibitors. HOPE Study: hope for all vascular patients?].
    MMW Fortschr Med; 1999 Oct; 141(42):66-7. PubMed ID: 10912112
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cardiovascular profile of the ACE-inhibitor Quinapril. Worshop report. Freiburg in Breisgau, 15-16 May 1992].
    Fortschr Med Monogr; 1992; 60():1-23. PubMed ID: 1366232
    [No Abstract]   [Full Text] [Related]  

  • 48. ACE inhibitors: back to prime time?
    Gupta M; Verma S; Mancini GB
    Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
    [No Abstract]   [Full Text] [Related]  

  • 49. Absence of association between angiotensin I-converting enzyme (ACE) DD genotype and the frequency of ACE inhibitor therapy.
    Sigusch HH; Surber R; Vogt S; Müller S; Hoffmann A
    Pharmazie; 1997 Jul; 52(7):565-6. PubMed ID: 9266596
    [No Abstract]   [Full Text] [Related]  

  • 50. [ACE-inhibitors: the indication spectrum grows wider].
    Fortschr Med Suppl; 1996; 178():1-10. PubMed ID: 9022411
    [No Abstract]   [Full Text] [Related]  

  • 51. Ramipril and risk of diabetes.
    Potyk DK
    JAMA; 2002 Jan; 287(2):186; author reply 186-7. PubMed ID: 11779250
    [No Abstract]   [Full Text] [Related]  

  • 52. [Cardiovascular diseases. Improvement of the endothelial function as strategic therapeutic aim].
    Z Kardiol; 1998 Jun; 87(6 Suppl Besserung):1-4. PubMed ID: 9698652
    [No Abstract]   [Full Text] [Related]  

  • 53. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The renin-angiotensin system in hypertension and heart insufficiency: current aspects in the use of ACE inhibitors].
    Greminger P; Vetter W
    Schweiz Rundsch Med Prax; 1988 Jun; 77(24):673-9. PubMed ID: 3041532
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination inhibition of the renin-angiotensin system: is more better?
    Krause MW; Fonseca VA; Shah SV
    Kidney Int; 2011 Aug; 80(3):245-55. PubMed ID: 21633407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical trials of renin-angiotensin antagonists in Japan].
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The suppression of the renin-angiotensin system during the treatment of cardiovascular diseases].
    Eliseev OM
    Ter Arkh; 1994; 66(8):80-3. PubMed ID: 7985166
    [No Abstract]   [Full Text] [Related]  

  • 59. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of ramipril on cardiovascular events in high-risk patients.
    Gavras H
    N Engl J Med; 2000 Jul; 343(1):65-6. PubMed ID: 10896546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.